| Autor: |
Mamontova AG; Regional Clinical Hospital № 3, 287 pr. Pobedy, Chelyabinsk 454021, Russian Federation., Usoltseva EN; South-Ural State Medical University, 64 Vorovskogo str., Chelyabinsk 454092, Russian Federation., Soloviev AG; Northern State Medical University, 51 Troitsky ave., Аrkhangelsk 163000, Russian Federation, e-mail: asoloviev1@yandex.ru. |
| Jazyk: |
ruština |
| Zdroj: |
Advances in gerontology = Uspekhi gerontologii [Adv Gerontol] 2020; Vol. 33 (6), pp. 1137-1141. |
| Abstrakt: |
Climacteric syndrome (CS) is considered to be a frequent manifestation of pathological menopause. Menopause associated not only with deficiency of sex steroids, decrease of melatonin secretion is observed. Perimenopausal melatonin deficiency syndrome (SPDM) is the complex of symptoms, which is often formed amid decrease of melatonin synthesis and clinically characterized by the prevalence of complaints of sleep disorders (problems), bodily pain, depression, anxiety/fears and somatic symptoms. CS and SPD are co-morbidities, that impair the «women menopausal health». The article presents the stratification algorithm of peri- and post-menopausal women with the co-morbid pathology of CS and SPDM for selection of differentiated therapy. The algorithm involves detection of indications for monotherapy with melatonin or synthetic genistein, and for combined treatment with menopausal hormone therapy. The usage of this concept is reasonable for improvement of treatment efficiency of co-morbid pathology of CS and SPDM, for quality of life improvement and for induction of active ageing of women of senior group. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
